Clinical characteristics | Infected (n = 37) | Non-infected (n = 54) | p | Odds ratioa (95% CI) |
---|---|---|---|---|
Year | ||||
2010 | 5 (14%) | 8 (15%) | 0.970 | |
2011 | 6 (16%) | 8 (15%) | ||
2012 | 4 (11%) | 9 (17%) | ||
2013 | 6 (16%) | 9 (17%) | ||
2014 | 8 (22%) | 11 (20%) | ||
2015 | 8 (22%) | 9 (17%) | ||
Age (years) | 50 (37–55) | 47 (36–58) | 0.587 | 1.00 (0.98–1.03) |
Gender (male) | 28 (76%) | 29 (54%) | 0.030 | 2.68 (1.09–7.00) |
Charlson Comorbidity Index | 1 (0–3) | 1 (0–3) | 0.839 | 1.21 (0.17–7.82) |
Transferred from peripheral hospital | 32 (86%) | 43 (80%) | 0.393 | 1.63 (0.53–5.62) |
IMV > 3 days prior to ECMO connection | 22 (59%) | 9 (17%) | 0.001 | 7.33 (2.86–20.3) |
RRT prior to ECMO connection | 11 (30%) | 4 (7%) | 0.005 | 5.29 (1.63–20.6) |
SOFA | 8 (6–12) | 8 (6–11) | 0.348 | 1.05 (0.94–1.17) |
SAPS II | 38 (32–49) | 37 (30–43) | 0.806 | 1.00 (0.97–1.03) |
ARDS | 35 (95%) | 37 (69%) | 0.001 | 8.04 (2.09–53.0) |
PaO2/FiO2 < 100 mmHg | 32 (86%) | 38 (70%) | 0.066 | 2.69 (0.93–8.97) |
Infection at admission | 31 (84%) | 33 (61%) | 0.017 | 3.28 (1.22–9.93) |
Chronic immunosuppressionb | 8 (78%) | 12 (78%) | 0.946 | 0.96 (0.34–2.63) |
Veno-venous support | 34 (92%) | 45 (83%) | 0.223 | 2.26 (0.62–10.8) |
Colonization | 16 (43%) | 3 (6%) | 0.001 | 12.9 (3.83–59.9) |